1110772-09-2 Usage
General Description
(1R,3S)-3-Aminomethyl-cyclopentanol is a chemical compound that belongs to the class of cyclopentanols. It is a chiral compound, with a stereocenter at the first carbon and the third carbon positions. The molecule contains an amine functional group (-NH2) and a hydroxyl group (-OH). (1R,3S)-3-Aminomethyl-cyclopentanol is commonly used as a chiral building block in organic synthesis and pharmaceutical manufacturing. Its chiral nature makes it a valuable starting material for the preparation of biologically active compounds, as it can potentially influence the pharmacological properties of the final product. (1R,3S)-3-Aminomethyl-cyclopentanol can also be used as a chiral ligand in asymmetric synthesis and catalysis. Additionally, (1R,3S)-3-Aminomethyl-cyclopentanol has potential applications in the development of new drugs, agrochemicals, and materials.
Check Digit Verification of cas no
The CAS Registry Mumber 1110772-09-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,1,0,7,7 and 2 respectively; the second part has 2 digits, 0 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 1110772-09:
(9*1)+(8*1)+(7*1)+(6*0)+(5*7)+(4*7)+(3*2)+(2*0)+(1*9)=102
102 % 10 = 2
So 1110772-09-2 is a valid CAS Registry Number.
1110772-09-2Relevant articles and documents
POLYFLUORINATED COMPOUNDS ACTING AS BRUTON TYROSINE KINASE INHIBITORS
-
, (2016/08/17)
Described herein is a novel series of multi-fluoro-substituted pyrazolopyrimidine compounds or salts thereof. These compounds are Bruton's tyrosine kinase (BTK) inhibitors. These compounds may possess better BTK inhibition selectivity and pharmacokinetic properties. Disclosed herein are the synthesis methods of these compounds. Disclosed herein are novel synthesis methods of the multi-fluoro-substituted benzophenone and substituted phenoxy benzene. Also disclosed are pharmaceutical compositions comprising the BTK inhibitors described herein. The present invention also relates to pharmaceutical formulations comprising the compounds described herein as active ingredients. The present invention also includes the therapeutic methods by administering the BTK inhibitors and their formulations to treat and inhibit autoimmune disease, hypersensitivity disease, inflammatory diseases and cancer.
Cycloalkyl-one-containing benzenesulphonamides
-
, (2008/06/13)
Cycloalkanol[1,2-b]indole-sulphonamides of the formula STR1 where appropriate in an isomeric form, and their salts are disclosed. These compounds are useful to inhibit platelet aggregation and to antagonize thromboxane A2.
